These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35386280)

  • 1. MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer.
    Hao S; Huang M; Xu X; Wang X; Huo L; Wang L; Gu J
    Front Genet; 2022; 13():857836. PubMed ID: 35386280
    [No Abstract]   [Full Text] [Related]  

  • 2. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
    Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
    Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
    Zhang M; Zhang J
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
    Zhang J; An L; Zhou X; Shi R; Wang H
    Ann Transl Med; 2021 Apr; 9(7):551. PubMed ID: 33987249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of
    Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
    Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.
    Ye H; Zhang N
    Comput Math Methods Med; 2021; 2021():1498924. PubMed ID: 34868337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer.
    Huang Z; Yang J; Qiu W; Huang J; Chen Z; Han Y; Ye C
    Front Oncol; 2022; 12():829777. PubMed ID: 35280773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
    Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 16. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
    Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
    Xu Q; Chen S; Hu Y; Huang W
    Front Immunol; 2021; 12():711433. PubMed ID: 34512634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.